Inhibrx Biosciences, Inc.
ozekibart (INBRX-109)
late line colorectal cancer
Resolved
77days ago
Phase 2 readout · Apr 21, 2026
What's at stake
Phase 2 trial results for ozekibart (INBRX-109) in late line colorectal cancer are due Apr 21, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“The Company also plans to discuss with the FDA the potential for accelerated regulatory pathways for ozekibart in fourth-line colorectal cancer and in refractory Ewing sarcoma.”